We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Bristol Myers Squibb Co
139 own
79 watching
Current Price
$65.48
$-0.5
(-0.76%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
137,563.47M
52-Week High
81.435
52-Week Low
63.07
Average Volume
5.49M
Dividend Yield
0.032969
P/E Ratio
16.83
Market Capitalization137,563.47M52-Week High81.43552-Week Low63.07Average Volume5.49MDividend Yield0.032969P/E Ratio16.83What does the Bristol Myers Squibb Co do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaborations with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; Apexigen, Inc. to evaluate Opdivo in combination with APX005M in patients with solid tumors; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Read More
How much money does Bristol Myers Squibb Co make?
News & Events about Bristol Myers Squibb Co.
PR Newswire
1month ago
Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030 Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030 PR Newswire PALM BEACH, Fla., May 5, 2023 FinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 5, 2023 /PRNewswire/ -- Breast...
Ticker Report
1month ago
Northeast Investment Management lowered its position in Bristol-Myers Squibb (NYSE:BMY Get Rating) by 14.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The firm owned 10,531 shares of the biopharmaceutical ...
Zolmax
2 months ago
Eudaimonia Partners LLC reduced its position in Bristol-Myers Squibb (NYSE:BMY Get Rating) by 3.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,490 shares of the biopharmaceutical companys stock after selling 323 ...
Business Wire
2 months ago
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high...
Business Wire
2 months ago
Bristol Myers Squibb (NYSE: BMY) today announced three-year follow-up results from the Phase 3 CheckMate -816 trial, demonstrating sustained clinical benefits with three cycles of Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with...
Frequently Asked Questions
Frequently Asked Questions
What is Bristol Myers Squibb Co share price today?
Can Indians buy Bristol Myers Squibb Co shares?
How can I buy Bristol Myers Squibb Co shares from India?
Can Fractional shares of Bristol Myers Squibb Co be purchased?
What are the documents required to start investing in Bristol Myers Squibb Co stocks?
What is today’s traded volume of Bristol Myers Squibb Co?
What is today’s market capitalisation of Bristol Myers Squibb Co?
What is the 52-Week High and Low Range of Bristol Myers Squibb Co?
What percentage is Bristol Myers Squibb Co down from its 52-Week High?
What percentage is Bristol Myers Squibb Co up from its 52-Week Low?
Current Price
$65.48
$-0.5
(-0.76%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.